International media has recently taken note of the work that Vielight is doing in Alzheimer’s Disease research. An article on Vielight’s work was published by a major UK newspaper, The Daily Telegraph. This article was picked up by a number of prominent newspapers. The list of publications includes another leading UK newspaper, Daily News, and Canada’s own National Post, Calgary Herald, Ottawa citizen, Windsor Star, and more.

However, we are not all about Alzheimer’s. There are at least twenty projects on our research schedule, some in collaboration with major research centers. The more notable ones include a traumatic brain injury clinical trial, a study on cognition, meditation, study on blood viscosity, enhancement of sports performance, the mechanism of cellular signaling, EEG responses to various transductions, autism, and PTSD. Information on the published ones can be accessed on this Vielight webpage.

Vielight Scientists about Vielight Research

According to Dr. Genane Loheswaran, PhD., Research Manager at Vielight, “We have a busy but rewarding research program that keeps our team highly motivated, and in search of new discoveries. The idea of covering vast areas of brain conditions and functions may strike many scientists as being too ambitious. However, when one understands that photobiomodulation (PBM), delivered in the right way, is able to treat and affect the power sources of cells – mitochondria, the horizon of possibilities broadens significantly. With PBM, multiple benefits may be expressed, resulting in improvements in numerous functional outcomes.

In our research, using the Vielight Neuro Gamma and Alpha, we consistently observe quick and significant changes in the brain. We record and measure these changes with techniques such as EEG and neuropsychological assessments. The feedback from consumers of Vielight devices continues to surprise even the skeptics in us. It gives us great motivation to pursue new modalities to treat various brain conditions. We also have the unique and exciting opportunity to explore the extent to which we can uncover the potential of the human brain.”

Dr. Lew Lim, PhD., CEO of Vielight, added, “The results of these research efforts tend to lead us to develop even more devices that help people in specific and effective ways. This has always been our goal. With our engineering team in full swing, we hope to translate ideas to make practical and affordable devices. Because the devices are novel and the first of their kind, the challenges are numerous. The high levels of creativity and expertise of our engineering team make these new products a reality.”

Online forums on PBM and Vielight are Expanding

Interest in PBM is growing, and so are the online communities interested in this subject. Much of the discussion on PBM effect on the brain has been dominated by Vielight. This reflects the amount of innovation that stems from the Vielight team mission to improve the quality of lives through cutting-edge knowledge in the field.

Vielight has a Facebook page, where we share company events and the knowledge relevant to PBM and our research. There are also several independent Facebook groups that are great forums for independent sharing. The most relevant is the Vielight Knowledge Exchange Group. We are notably absent or infrequent in our participation for a couple of reasons. One, not to influence sharing of positive, as well as negative experiences. Another, we are not licensed to provide medical advice. Other active Facebook groups are Brain Photobiomodulation Exchange and Research, and Neuro-Photobiomodulation PEMF TDCS TMS.

Where to participate in Alzheimer’s Disease Clinical Trials

There are now two active sites recruiting participants for the Vielight RX Gamma Alzheimer’s Disease pivotal clinical trial. They are St. Michael’s Hospital, Toronto, and Bruyere Research Institute, Ottawa. In addition, the following sites will be opening soon: Progressive Medical Research, Port Orange, Florida, Healthtech Connex, Surrey, British Columbia, and Boston University School of Medicine. When new sites will be open for registration and recruitment, we will make announcements in our newsletter and social media. To enquire about participation in this trial, contact the managers for the trial, Applied Health Research Centre (AHRC) at St. Michael’s Hospital in Toronto.

Vielight welcomes Mingyang Chen, Quality and Product Engineer

Mingyang Chen joins Vielight as Quality and Product Engineer, bringing his expertise, which we need, as the company grows. Mingyang graduated from McGill University with a Masters’ degree in Materials Engineering. He will help us to meet our product quality goals and to improve trouble-shooting processes. He brings his experience in quality management, product development and software coding. Such continual strengthening of our team will help us to develop and release ground-breaking products that surprise with their practicality.

The post Vielight Research Grows first appeared on Vielight Inc - Deutsch.

The post Vielight Research Grows appeared first on Vielight Inc - Deutsch.

Report from Dr. Lew Lim, the Founder & CEO of Vielight:

“2019 has been particularly busy for Vielight. We pushed the frontiers of brain photobiomodulation (PBM) understanding, translating ideas into cutting-edge products. This calls upon the combination of engineering skills, science and user safety.

In 2019 we released updated versions of the Neuro Alpha and Gamma devices, as well as the all new X-Plus. The X-Plus has been designed to be versatile. It can be used on its own on most parts of the body (the eyes being an exception). It is also complementary to the Neuro Alpha and Gamma devices. The X-Plus can be placed on the head to deliver more photons to areas of the brain which are not covered by the Neuro.

In addition to these devices, we are finalizing other new products such as the Neuro Pro, a vagus nerve stimulation device and a chronic pain treatment device.

An Important Year

This has also been an important year in terms of trials and studies. The pivotal Alzheimer’s disease trial commenced in the summer. This is a 286-subject, double-blind, eight-sight clinical trial held in both Canada and USA.

Furthermore, we have also started a controlled clinical trial for traumatic brain injury. We and our research collaborators have planned new studies covering several clinical and non-clinical indications. We will keep you posted! More exciting news came from Australia, where independent university researchers have started their Parkinson’s Disease clinical trials using the Vielight Gamma.

Earlier this year, our published paper revealed for the first time that the brain produces unique electrophysiological and connectivity responses to gamma wave. The most significant lesson out of the study was the clear evidence that the brain responds significantly to intranasal-transcranial stimulation by the Vielight Neuro Gamma device. The evidence confirms that neurological modulation can be induced by the device, despite the low power and dose of the Vielight devices. Furthermore, the University of California and the University of Sydney in Australia supported these results with their imaging from fMRI. Another research study is being initiated to explain the mechanisms of why the Vielight devices are able to elicit such responses deep within the brain.

Looking forward

According to FDA guidelines, our devices are categorized as low-risk general wellness devices. We continue to respect the boundaries within which we are able to present our devices. We believe that solid reproducible scientific evidence should prevail over speculative claims. For this reason, we maintain the discipline to practice restrain and patience in making claims regarding our devices. Meanwhile, we continue to actively seek empirical evidence to support our hypotheses embedded in the designs of our products.

I wish to thank our marvelous, dedicated and talented staff who have been quick on their feet and exercised total professionalism in their work. I also wish to thank and am grateful to our collaborators and researchers, who have continued to believe in us, as we explore new areas of knowledge. Without the practitioners and customers who believed in our technology, we would be nowhere today. There is so much more to be discovered!

I humbly thank you all for your support and send you Season’s greetings!”

Imaging Shows the Effect of Neuro Alpha on Managing Movement

Using fMRI, clinical investigators at the University of Sydney showed that the Neuro Alpha can affect a healthy human brain in interesting and non-intuitive ways. The paper published in the journal, Neuroscience, is an exploration of whether near infrared light can change patterns of resting (task-negative) and/or evoked (task-positive; e.g. finger-tapping) brain activity in healthy, young human subjects.

In this study, the test subjects used the active or sham Vielight Neuro Alpha, while their brains were scanned using fMRI (functional magnetic resonance imaging). The results showed that 810 nm near infrared (NIR) light had no effect on cerebral blood flow. However, there were clear differences between the active and sham sessions in the patterns of evoked brain activity after finger-tapping actions. The evoked brain regions included those that controlled the performed movements, as well as the default mode network, which were targeted by the Neuro Alpha device. The overall effect of the NIR light from the Neuro Alpha was either suppression or reduction in the corresponding brain activity, after movements are initiated, which is desirable to control movements.

Dr. Lim interpreted the significance of the findings of this study. “The findings show that PBM with the Vielight Alpha helps to control movements, by helping the brain to avoid uncontrolled continuation of movements after they have been initiated. Without this, there is the risk of dyskinesia (impairment of voluntary movements) in movement disorders, such as that observed in Parkinson’s.”

Eventful November

Vielight was involved with several conferences and presentations this November. We were there for the Biohacker Summit in Helsinki, Finland, Transtech 2019 in Palo Alto, California and MEDICA 2019 in Dusseldorf, Germany. In addition, Dr. Lim delivered a 3-hour workshop in Perth, Western Australia.
This year, we noticed a significant uptick in the awareness of the Vielight technology, as well as in the ownership of Vielight devices. We are thankful to all patrons who set aside time to meet with us to get updates and deeper understanding of our technology.

Vielight is returning to A4M Conference 2019

This year Vielight is going to be present at the world’s largest aging related conference, A4M, in Las Vegas. The 2019 event is the 27th congress put together by the American Academy of Anti-Aging Medicine (A4M). Drop by our booth from 13 to 15 of December 2019 to have a chat and to try our devices. We are looking forward to seeing you at A4M 2019.

Welcoming Ciara Ross into the team

We extend a warm welcome to Ciara Ross in joining Vielight this month. Ciara has a degree in Philosophy and is a TESOL certified English language teacher. She has vast experiences as a journalist, researcher, administrator, an international coordinator in the teaching of English worldwide and is an expert in information technology. With her affable personality and love for helping people, we welcome Ciara as our customer service team member.

The post Vielight Report 2019 first appeared on Vielight Inc - Deutsch.

The post Vielight Report 2019 appeared first on Vielight Inc - Deutsch.